Treatment of psoriasis with fumaric acid esters (Fumaderm®)

  title={Treatment of psoriasis with fumaric acid esters (Fumaderm{\textregistered})},
  author={Ulrich Mrowietz and Peter Altmeyer and Thomas Bieber and Martin R{\"o}cken and Rudolf E. Schopf and Wolfram Sterry},
  journal={JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
• JDDG • 1610-0379/2007/0508-0716 Definition Systemic treatment of severe psoriasis with fumaric acid esters has been approved in Germany since 1995. The clinical efficacy in psoriasis is documented in studies. Fumaderm and Fumaderm initial are available as standardized products to treat psoriasis. Systemic treatment of moderate to severe psoriasis with Fumaderm follows an established dosage scheme which can be varied individually. A significant improvement of the skin condition can be observed… Expand
Fumaric acid and its derivatives in the treatment of psoriasis vulgaris: our experience in forty-one patients.
In this trial, an improvement in cutaneous psoriasis was observed in 46% of treated patients, while side effects were noticed in 52% of patients; only three patients dropped out due to gastrointestinal problems. Expand
Dimethyl fumarate is efficacious in severe plaque psoriasis
Dimethyl fumarate is effective and safe in the systemic treatment of adults with severe psoriasis (physician global assessment), and this is the first report of dimethyl fumaric acid esters in a severely affected population with plaque Psoriasis. Expand
Fumarates for treatment of psoriasis
  • A. Egeberg
  • Medicine
  • The British journal of dermatology
  • 2016
An abridged version of the Cochrane Review of fumarates for the treatment of psoriasis is presented and the authors find limited and low-quality evidence to support superiority offumarates compared with placebo, and very low- quality evidence of studies comparing fumarate to methotrexate. Expand
Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus
The results of an expert meeting which was convened to deliver clinician‐agreed consensus and real‐world guidance on the clinical use of DMF in moderate‐to‐severe chronic plaque psoriasis are reported. Expand
Direct Comparison of Risankizumab and Fumaric Acid Esters in Systemic-Therapy-Naive Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial.
Risankizumab was found superior to FAEs, providing earlier and greater improvement in psoriasis outcomes that persisted with continued treatment, and more favorable safety results consistent with the known safety profile. Expand
Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?
Dimethyl fumarate is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing-Remitting Multiple Sclerosis and the potential benefits of FAEs against other diseases that appear pathogenically different but share the pathologies of oxidative stress and inflammation are currently investigated. Expand
Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris
The present guidelines are focused on the initiation and management of systemic therapies in cases of moderate-to-severe plaque-type psoriasis in adults to optimize treatment response, adherence and quality of life. Expand
Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate‐to‐severe chronic plaque psoriasis: a randomized, double‐blind, Fumaderm®‐ and placebo‐controlled trial (BRIDGE)
Fumaric acid esters (FAEs) are recommended in international guidelines for induction and long‐term treatment of adults with moderate‐to‐severe chronic plaque psoriasis. The fixed combinationExpand
Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action.
Molecular studies showed that a clear preservation of myelin and axonal density in the plaque in the mouse model of central nervous system demyelination, MOG-induced experimental autoimmune encephalomyelitis, revealed that this is based on the antioxidative mechanism of action via induction of the transcription factor Nrf-2. Expand
Drug survival of fumaric acid esters for psoriasis: a retrospective study
Fumaric acid esters have been used for over 30 years in the management of psoriasis and are still being used in clinical practice. Expand


Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use
  • Mrowietz, Christophers, Altmeyer For The German Fumaric Acid Ester Consens
  • Medicine
  • The British journal of dermatology
  • 1999
Experimental and clinical information on FAE in psoriasis is reviewed and guidelines for the clinical use of FAEs derived from a consensus meeting of leading experts are provided. Expand
Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study
The results of this multicentre study showed in a large number of patients that systemic FAE treatment is effective in severe psoriasis vulgaris and Transient eosinophilia seems to be a characteristic feature of FAE therapy, while lymphocytopenia is usually mild. Expand
Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients.
Fumaric acid derivatives were found to be effective and safe in the treatment of psoriasis and indicated statistically significant superiority of the fumaric Acid derivatives over placebo. Expand
Long‐term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis
Therapy with fumaric acid esters (FAE) has been shown to be safe and effective in patients with severe psoriasis in several clinical studies with limited follow‐up periods. Expand
Topical Calcipotriol plus Oral Fumaric Acid Is More Effective and Faster Acting than Oral Fumaric Acid Monotherapy in the Treatment of Severe Chronic Plaque Psoriasis vulgaris
The combination of calcipotriol and FAEs is significantly more effective and faster acting than FAE monotherapy in the treatment of severe plaque psoriasis and therefore has a slight FEA-sparing effect and therefore a superior benefit/risk ratio. Expand
S3‐Leitlinie zur Therapie der Psoriasis vulgaris
Untersuchungen zur Einschrankung der Lebensqualitat bei den Patienten haben ergeben, dass durch die Erkrankung in Abhangigkeit vom Schweregrad eine erhebliche Belastung in Form einer Behinderung bestehen kann. Expand
Das Wirkungs- und Sicherheitsprofil von Fumarsäureestern in der oralen Langzeittherapie bei schwerer therapieresistenter Psoriasis vulgaris Eine Untersuchung an 83 Patienten
The therapeutic effect and the side effects of fumaric acid derivatives used in treatment of psoriasis vulgaris have been subjects of controversy for more than 30 years and are believed to have been used even for long-term application. Expand
Das Wirkungs - und Sicherheitsprofil von Fumarsäureestern in der oralen Langzeittherapie bei schwerer thera - pieresistenter Psoriasis vulgaris
  • Hautarzt
  • 1996